UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 360

Sortiert nach

Safety of Semaglutide

Frontiers in endocrinology (Lausanne), 2021-07, Vol.12, p.645563

2021

Link zum Volltext

Verfügbarkeit prüfen

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

Journal of the American Society of Nephrology, 2017-04, Vol.28 (4), p.1023-1039

2017

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes

Cardiovascular research, 2020-04, Vol.116 (5), p.916-930

2020

Link zum Volltext

Verfügbarkeit prüfen

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

Nature reviews. Nephrology, 2017-10, Vol.13 (10), p.605

2017

Link zum Volltext

Verfügbarkeit prüfen

Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial

The lancet. Diabetes & endocrinology, 2016-11, Vol.4 (11), p.893-902

2016

Link zum Volltext

Verfügbarkeit prüfen

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

Nature reviews. Nephrology, 2014-02, Vol.10 (2), p.88

2014

Link zum Volltext

Verfügbarkeit prüfen

Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups

Journal of gastroenterology and hepatology, 2013-04, Vol.28 (4), p.664-670

2013

Link zum Volltext

Verfügbarkeit prüfen

The role of phosphorus, magnesium and potassium availability in soil fungal exploration of mineral nutrient sources in Norway spruce forests

The New phytologist, 2016-07, Vol.211 (2), p.542-553

2016

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

Cardiovascular diabetology, 2022-04, Vol.21 (1), p.63-63, Article 63

2022

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum: Safety of Semaglutide

Frontiers in endocrinology (Lausanne), 2021-11, Vol.12, p.786732-786732

2021

Link zum Volltext

Verfügbarkeit prüfen

Indole-3-carboxyaldehyde does not reverse the intestinal effects of fiber-free diet in mice

Frontiers in endocrinology (Lausanne), 2024, Vol.15, p.1362711-1362711

2024

Link zum Volltext

Verfügbarkeit prüfen

Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease

Pancreas, 2010-11, Vol.39 (8), p.1185-1190

2010

Link zum Volltext

Verfügbarkeit prüfen

l-valine is a powerful stimulator of GLP-1 secretion in rodents and stimulates secretion through ATP-sensitive potassium channels and voltage-gated calcium channels

Nutrition & diabetes, 2024-06, Vol.14 (1), p.43-11, Article 43

2024

Link zum Volltext

Verfügbarkeit prüfen

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors

The lancet. Diabetes & endocrinology, 2015-05, Vol.3 (5), p.367-381

2015

Link zum Volltext

Verfügbarkeit prüfen

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes

Scientific reports, 2021-05, Vol.11 (1), p.10624-10624, Article 10624

2021

Link zum Volltext

Verfügbarkeit prüfen

Smoking Is Related to Pancreatic Fibrosis in Humans

The American journal of gastroenterology, 2011-06, Vol.106 (6), p.1161-1166

2011

Link zum Volltext

Verfügbarkeit prüfen

Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?

Diabetes/metabolism research and reviews, 2023-11, Vol.39 (8), p.e3699-e3699

2023

Link zum Volltext

Verfügbarkeit prüfen

Incretin-based drugs and renoprotection—is hyperfiltration key?

Kidney international, 2015-03, Vol.87 (3), p.660-661

2015

Link zum Volltext

Verfügbarkeit prüfen

Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390

Diabetes care, 2023-05, Vol.46 (5), p.e120-e120

2023

Link zum Volltext

Verfügbarkeit prüfen

In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice

Diabetes (New York, N.Y.), 2024-05, Vol.73 (5), p.671

2024

Link zum Volltext

Verfügbarkeit prüfen

Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis

Annals of epidemiology, 2013-07, Vol.23 (7), p.415-421

2013

Link zum Volltext

Verfügbarkeit prüfen

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

Diabetologia, 2016-12, Vol.59 (12), p.2588-2593

2016

Link zum Volltext

Verfügbarkeit prüfen

The clinical significance of pancreatic steatosis

Nature reviews. Gastroenterology & hepatology, 2011-03, Vol.8 (3), p.169

2011

Link zum Volltext

Verfügbarkeit prüfen

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Diabetologia, 2016-07, Vol.59 (7), p.1412-1421

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 360

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(333)
Mit Volltextzugriff
(321)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(275)
Life Sciences & Biomedicine
(236)
Humans
(196)
Female
(121)
Male
(117)
Adult
(77)
Middle Aged
(71)
Biological And Medical Sciences
(60)
Aged
(51)
Medical Sciences
(42)
Treatment Outcome
(40)
Diabetes
(34)
Endocrinology & Metabolism
(33)
Animals
(31)
Patients
(29)
Social Sciences
(29)
Psychology
(28)
Risk Factors
(28)
Clinical Trials
(26)
Diabetes Mellitus, Type 2 - Drug Therapy
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Safety of Semaglutide

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups

The role of phosphorus, magnesium and potassium availability in soil fungal exploration of mineral nutrient sources in Norway spruce forests

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

Corrigendum: Safety of Semaglutide

Indole-3-carboxyaldehyde does not reverse the intestinal effects of fiber-free diet in mice

Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease

l-valine is a powerful stimulator of GLP-1 secretion in rodents and stimulates secretion through ATP-sensitive potassium channels and voltage-gated calcium channels

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes

Smoking Is Related to Pancreatic Fibrosis in Humans

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?

Incretin-based drugs and renoprotection—is hyperfiltration key?

Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390

In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice

Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

The clinical significance of pancreatic steatosis

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Suchergebnisse filtern